Can Ascletis ASC30 compete with established oral GLP-1 treatments?
Ascletis reports up to 1.7-point HbA1c reduction and 4.4% weight loss with oral ASC30, as larger trials must confirm safety and efficacy.
Pharma & Biotech
Pharma & Biotech
Can Ascletis ASC37 become a once-monthly triple agonist for obesity?
Ascletis says ASC37 beat tirzepatide in obese mice, but human dosing, safety and durability remain untested ahead of a planned U.S. IND.
Pharma & Biotech
Ascletis advances once-monthly ASC36 and ASC36_35 obesity injections into FDA review
Discover why Ascletis’ monthly ASC36 and ASC36_35 obesity drugs matter, and which clinical risks could determine their future.
Pharma & Biotech
Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?
Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.
Pharma & Biotech
Is oral GLP-1 finally viable? Inside Ascletis Pharma’s U.S. trial for ASC30
Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.
Pharma & Biotech
Can Ascletis’ denifanstat reshape acne treatment by targeting fatty acid synthesis?
Ascletis' acne drug denifanstat advances with NDA acceptance in China. Explore how FASN targeting could disrupt acne care and redefine systemic treatments.